OUR PIPELINE

MAKING
THE GREAT,
GREATER

We analyze the unmet needs of patients—continuously looking for ways to further improve therapies for those who need them. To help realize this goal, our teams have been hard at work to grow our portfolio of oncology, critical care, and orphan disease treatments through the development of biologics and small molecules.

THE TEAMS
AT WORK

Small Molecule Formulation Development

Mission Viejo, CA

Biologics Formulation Development

Cambridge, MA

Medical and Operations

Woodcliff Lake, NJ

OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES

RYANODEX® (dantrolene sodium) for Injectable Suspension

Malignant Hyperthermia Approved

Exertional Heat Stroke Investigational Indication
Clinical Trial Planned for August 2018

Psychostimulant Drug-Induced Toxicity Investigational Indication, Clinical Trial Ongoing

Nerve-Agent Induced Brain Damage Investigational Indication

BENDEKA® (bendamustine hydrochloride) Injection

Chronic Lymphocytic Leukemia (CLL) Approved

Indolent B-cell Non-Hodgkin Lymphoma (NHL) Approved

Docetaxel Injection Non-Alcohol Formula

Breast Cancer (BC) Approved

Non-Small Cell Lung Cancer (NSCLC) Approved

Hormone Refractory Prostate Cancer (HRPC) Approved

Gastric Adenocarcinoma (GC) Approved

Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN) Approved

PEMFEXY™ (pemetrexed injection)

Non-Small Cell Lung Cancer (Nsclc) Tentative Approval

Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer in Combination With Cisplatin Tentative Approval

Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Four Cycles of Platinum-Based First-Line Chemotherapy, As Maintenance Treatment Tentative Approval

Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer After Prior Chemotherapy as a Single Agent Tentative Approval

Malignant Pleural Mesothelioma Whose Disease is Unresectable or Who Are Otherwise Not Candidates for Curative Surgery in Combination with Cisplatin Tentative Approval

Fulvestrant

Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy  Investigational Indication, Clinical Trial Ongoing